A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples